Lexeo Therapeutics (NASDAQ:LXEO) Upgraded at Chardan Capital

Chardan Capital upgraded shares of Lexeo Therapeutics (NASDAQ:LXEO) to a strong-buy rating in a research report sent to investors on Tuesday morning,Zacks.com reports.

Other equities analysts have also recently issued reports about the stock. JPMorgan Chase & Co. cut their target price on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a report on Thursday, June 25th. Wall Street Zen upgraded shares of Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings raised shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, July 10th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $18.75.

Lexeo Therapeutics Stock Up 0.9%

Shares of NASDAQ LXEO opened at $4.35 on Tuesday. The business has a 50-day moving average price of $4.71 and a 200 day moving average price of $5.84. The stock has a market cap of $341.57 million, a PE ratio of -3.00 and a beta of 1.42. Lexeo Therapeutics has a 52-week low of $4.03 and a 52-week high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.04. Sell-side analysts anticipate that Lexeo Therapeutics will post -1.21 earnings per share for the current year.

Insider Transactions at Lexeo Therapeutics

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 25,947 shares of the business’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total transaction of $116,242.56. Following the transaction, the chief executive officer owned 377,817 shares in the company, valued at approximately $1,692,620.16. The trade was a 6.43% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Narinder Pal Bhalla sold 22,306 shares of the stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $4.42, for a total value of $98,592.52. Following the transaction, the insider directly owned 82,194 shares of the company’s stock, valued at approximately $363,297.48. This trade represents a 21.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 62,204 shares of company stock valued at $280,089. 2.00% of the stock is owned by insiders.

Institutional Trading of Lexeo Therapeutics

A number of institutional investors have recently modified their holdings of LXEO. AQR Capital Management LLC raised its position in Lexeo Therapeutics by 370.0% in the first quarter. AQR Capital Management LLC now owns 50,337 shares of the company’s stock worth $175,000 after acquiring an additional 39,627 shares in the last quarter. Millennium Management LLC boosted its position in shares of Lexeo Therapeutics by 654.8% during the 1st quarter. Millennium Management LLC now owns 1,071,489 shares of the company’s stock worth $3,718,000 after purchasing an additional 929,538 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Lexeo Therapeutics during the 1st quarter worth $85,000. Rhumbline Advisers grew its stake in shares of Lexeo Therapeutics by 19.8% during the 1st quarter. Rhumbline Advisers now owns 30,192 shares of the company’s stock worth $105,000 after purchasing an additional 4,995 shares during the period. Finally, Cerity Partners LLC purchased a new position in shares of Lexeo Therapeutics in the 2nd quarter valued at about $50,000. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.